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1. Introduction
Lung cancer is the leading cause of death in men and the
second in women in the developed world. Between 60 and
70% of these tumors are diagnosed in advanced stages, pre-
senting symptoms resulting from neoplastic disease itself.
There are several therapeutic endoluminal as dilation of the
airway, electrocautery, argon therapy, laser therapy, photo-
dynamic therapy, cryotherapy and brachytherapy especially
bronchus.
TheBRTendobronchial: involves placing, throughbroncho-
scope, a guide catheter bronchus and subsequent application
of a radioactive source using amanual or automatic afterload-
ing.
2. Historical evolution
Lung brachytherapy is a technique that gives detailed look at
present is being rediscovered. A ﬁrst “pioneer stage” begins in
the ﬁrst third of the twentieth century. Yankauer Sydney was
in NewYork (USA), who in 1922 published the implementation
of capsules Radon (222Rn). Kernan later in 1933 will be the ﬁrst
to publish a series of brachytherapy in trachea and bronchus
in 10 patients using 222Rn seeds.
Simultaneously Grajan and Singer, also in 1933 made the
ﬁrst interstitial implant between 1936, a thoracotomy with
222Rn seeds. Pool published a large series of 42 patients that
were included in the primary tumors and recurrences.
A second stage called “modern era” began in the 70s with
the introduction of new techniques using interstitial iso-
topes such as iodine (131I) and palladium (103Pd) in obstructive
tumors. These techniques had a higher security proﬁle on the
professionally exposed personnel and patients themselves. It
is from the 80s, when there appear publications using after-
loading systems in bronchial brachytherapy.
Today we speak of the “contemporary stage”, where the
brachytherapybronchusdevelops current technological devel-
opment, incorporating the new information technologies,
electronics and telecommunications have led to the intro-
duction of new imaging devices such as multislice CT high
resolution 3D virtual simulation systems and 3D planning
systems algorisms fast and accurate calculation. They have
introduced automatic remote loading high dose rate (HDR) for
easy handlingwith radioactive sources of 192Irmillimeterwith
a high safety proﬁle and cost effectively.
3. General indications for endobronchial
brachytherapy
3.1. Palliative treatment
In primitive or metastatic malignant tumors that involve light
and are not subsidiaries of treatment (surgery). It is the main
indication and can be divided into two groups:
1. Symptomatic patients.
• Dyspnea, cough, hemoptysis and repeated obstructive
pneumonia.
2. Asymptomatic patients
• Endobronchial recurrence of carcinomas underwent
surgery, chemotherapy, radiation therapy or previous
treatment, affecting the bronchial tree.
• Desobstructivas complement other palliative techniques
(laser, cryotherapy, etc).
3.2. Curative treatments
• Surgical resection of lung cancer resection edges affected.
• Tumors in situ in patients not candidates for radical surgery.
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• Tumors stage IA (T1N0M0) limited to the bronchial wall in
cases for surgical treatment, for medical reasons or due to
patient choice.
• Treatment with external radiotherapy in tumors, endo-
bronchial brachytherapy as adding boost.
4. Contraindications
• Inability to correctly position the catheter, or bypass the
distal end of the tumor.
• Severe obstruction of the trachea, and main bronchus
greater than 60%.
• Severe obstruction of the tracheal lumen (>70%).
• Obstruction or extrinsic compression endobronchial
involvement.
• Peripheral tumors.
• General contraindications to bronchoscopy.
• Life expectancy of less than a month.
• Status (ECOG>2, Karnoffsky Index<60).
• Patients eligible for surgery.
5. Results and complications
In palliative care the most relevant is to evaluate the clin-
ical beneﬁt resulting from the improvement of obstructive
symptoms and to quantify the degree of endoscopic tumor
regression. In curative primary goal is to increase the survival
and less symptom control.
The most common acute complications are cough, mild
infections, pneumothorax, bronchospasm, heart rhythm dis-
orders and pain in the chest wall.
Late complications such as fatal hemoptysis are the most
serious complication that can be observed. There are other
complications such as tracheoesophageal ﬁstulas, bronchitis
and tracheomalacia.
